SYNERGY(SZ:300636)2021-04-01 16:00Financial Performance - The company's operating revenue for 2020 was ¥435,420,102.66, representing a 5.41% increase from ¥413,058,080.41 in 2019[20]. - The net profit attributable to shareholders for 2020 was ¥70,051,149.39, a significant increase of 45.01% compared to ¥48,309,308.09 in 2019[20]. - The net cash flow from operating activities reached ¥80,066,182.17, a remarkable increase of 383.20% from -¥28,272,033.86 in 2019[20]. - The basic earnings per share for 2020 was ¥0.5434, up 45.02% from ¥0.3747 in 2019[20]. - The total assets at the end of 2020 amounted to ¥1,467,668,918.00, reflecting a 44.50% increase from ¥1,015,711,377.14 at the end of 2019[20]. - The company reported a weighted average return on equity of 9.43% for 2020, an increase of 2.38% from 7.05% in 2019[20]. - The company’s net profit after deducting non-recurring gains and losses was ¥67,269,500.99, which is a 38.40% increase from ¥48,603,779.84 in 2019[20]. - The company achieved a consolidated net profit of CNY 70,051,149.39 for the year 2020, with distributable profits amounting to CNY 63,024,677.90[125]. - The total cash dividend amount (including other methods) is CNY 10,932,693.20, which accounts for 100% of the distributable profits[125]. Market and Sales Strategy - The company is actively expanding its international market presence, which has led to increased operational risks associated with foreign currency exchange[6]. - The company has highlighted the impact of national healthcare reforms and new pharmaceutical policies on its operations and market competition[4]. - The company is focusing on expanding its product line and enhancing its sales team to strengthen market presence and internal management[37]. - The company’s sales strategy includes direct sales and partnerships with intermediaries, enhancing its market reach both domestically and internationally[35]. - The company reported a significant increase in domestic sales, which rose by 166.71% to ¥82.56 million, while foreign sales decreased by 7.65% to ¥352.86 million[69]. - The company launched several new products, including Tegrelor, Vildagliptin, Rivaroxaban, and Agomelatine, which are expected to contribute to revenue growth as their global patents expire[37]. Research and Development - The company has a strong focus on research and development of new products and technologies to maintain its competitive edge in the pharmaceutical industry[4]. - The company maintains a strong R&D team of 304 personnel, ensuring high investment in research and development to support market expansion and innovation[46]. - Research and development expenses amounted to 35,300,660.48 CNY, representing 8.11% of total operating revenue, maintaining a high investment level[79]. - The company has established several research and innovation platforms, including the "Jiangxi Province Characteristic Raw Material Drug Engineering Technology Research Center" and "National Postdoctoral Research Workstation" to enhance its R&D capabilities[44]. - The company conducted 10 R&D projects during the reporting period, with 6 projects completing small-scale trials and achieving qualified samples[79]. Environmental and Safety Management - The company is committed to environmental standards, ensuring that all waste produced during manufacturing meets national regulations[5]. - The company is facing increased costs related to pollution control as environmental regulations become stricter[5]. - The company has established a comprehensive environmental protection system, with significant investments in pollution control and waste management facilities, including a 120 tons/day MVR evaporator and a 156 tons/day four-effect evaporator[178]. - The company has a dedicated environmental protection team of 48 personnel and utilizes various monitoring systems for wastewater and air quality[180]. - The company has established a comprehensive safety management system, including a safety production committee led by the general manager, to oversee safety operations[113]. Financial Governance and Shareholder Rights - The company emphasizes the protection of minority shareholders' rights and interests in its profit distribution process[124]. - The company has fulfilled all commitments made by its controlling shareholders and related parties during the reporting period[129]. - The company has committed to protecting the legal rights of investors and ensuring compliance with relevant laws and regulations[136]. - The company has implemented an employee stock incentive plan, granting 1,298,000 restricted shares to 82 participants, aimed at aligning employee interests with company performance[144]. - The company plans to maintain a clear and transparent profit distribution policy, ensuring compliance with its articles of association and shareholder resolutions[124]. Future Outlook and Strategic Initiatives - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB[130]. - The company plans to utilize idle raised funds of up to RMB 60 million temporarily to supplement working capital[101]. - The company will actively seek mergers and acquisitions to extend its industrial chain and enhance its market position[109]. - The company plans to submit domestic registration files for 8 products in 2021, including drugs such as Rebapide and Enalapril[104]. - The company aims to expand its sales team significantly to enhance marketing efforts in both domestic and international markets[105].